What is AI-Driven Diabetic Retinopathy Screening?

AI-driven diabetic retinopathy screening involves the use of deep learning technology and CNN algorithms for analysis of the retinal fundus images to diagnose diabetic retinopathy, one of the top reasons for preventable blindness in people who have diabetes. AI-driven platforms obtain retinal fundus images using non-mydriatic retinal cameras and provide diagnosis or referral advice at the time of care. This is conducted to screen patients suffering from diabetic retinopathy in primary care, endocrinology and community healthcare settings without the need for immediate consultation with an ophthalmologist.

Unlike traditional retinal screening methods, AI-based technology provides rapid diagnostic assistance in the context of standard diabetes check-ups. This increases the accessibility of screening and facilitates the incorporation of eye examination into the diabetes management process. The U.S. market offers autonomous AI solutions, where diagnosis is provided independently of any physician’s intervention, and assistive AI tools to help professionals analyze retinal scans.

Source: Polaris Market Research Analysis

U.S. AI-Driven Diabetic Retinopathy Screening Market Driver Impact Analysis

The U.S. AI-driven diabetic retinopathy screening market is projected to grow at a CAGR of 21.74% through 2034. The table below highlights the major growth drivers and their expected impact across care settings and regions.

Market Driver	Est. CAGR Impact	Relevance	Impact Timeline
High and growing U.S. diabetes prevalence driving unmet screening demand	+2.4%	National highest in South and Southeast states	Short to medium term
CMS reimbursement expansion for autonomous AI diabetic retinopathy screening under Medicare and Medicaid	+2.1%	National Medicare Advantage and Medicaid managed care	Short to medium term
Integration of AI retinal screening into primary care chronic disease management workflows	+1.7%	Nationwide concentrated in FQHC and large health systems	Medium term (2–4 years)
Payer-directed preventive screening programs deploying AI retinal imaging across diabetic member populations	+1.4%	Medicare Advantage, commercial payers, employer plans	Medium to long term
Expansion of AI screening into retail pharmacy, urgent care, and community health settings	+1.1%	High-prevalence states: TX, FL, GA, NC, AZ	Medium term
Multi-disease AI retinal analysis expanding per-scan clinical value	+0.8%	National	Long term

* Indicative estimates based on market context and analyst judgment. Figures reflect relative driver weight, not additive CAGR contributions. Source: Polaris Market Research Analysis.

U.S. AI-Driven Diabetic Retinopathy Screening Market Industry Dynamics

• Expanding CMS coverage for AI-based diabetic retinopathy screening under the 2024 Physician Fee Schedule is reducing reimbursement uncertainty and accelerating health system adoption of autonomous AI platforms at primary care sites.
• Growing deployment of non-mydriatic fundus cameras in primary care offices and FQHCs is creating the hardware infrastructure base necessary for widespread autonomous AI screening program rollout.
• Physician awareness gaps regarding AI retinal screening program integration and workflow optimization continue to slow adoption rates in smaller independent primary care practices.
• Increasing collaboration between AI retinal screening companies and electronic health record vendors is reducing integration friction and enabling automated patient recall, result documentation, and referral generation within existing care workflows.

U.S. AI-Driven Diabetic Retinopathy Screening Market Drivers, Restraints and Opportunities

How Is U.S. Diabetes Prevalence Driving Growth in the AI-Driven Diabetic Retinopathy Screening Market?

Increase in diabetes patients in the US is among the key drivers of AI-driven screening for diabetic retinopathy in the country. Based on data from 2023, the American Diabetes Association estimates that more than 40 million Americans, which constitutes 12% of the U.S. population, are living with diabetes. This includes over 2 million people with type 1 diabetes, among them approximately 314,000 children and adolescents(Source: diabetes.org). Annual retinal examinations are recommended for every person with diabetes, a large share of patients remain unscreened each year. This unmet need has created strong demand for AI-enabled point-of-care screening in primary care and community healthcare settings.

How is CMS Reimbursement Policy Reshaping the AI-Driven Diabetic Retinopathy Screening Market?

CMS reimbursement remains one of the major drivers of the growth of the AI diabetic retinopathy screening market in the US. It allows making screening profitable and supports the implementation of the technology among hospitals, healthcare organizations, and primary care providers. The expansion of reimbursement policies helps develop the value-based care and preventive screening programs for the treatment of diabetes. As a result of this development, in April 2026, the Centers for Medicare & Medicaid Services adopted the final Medicare Advantage and Part D Payment Policies for 2027(Source: www.cms.gov).

What Challenges Threaten U.S. AI-Driven Diabetic Retinopathy Screening Market Expansion?

Reimbursement Permanence and Workflow Integration

The current system of payment under CMS is based on Category III CPT codes that are meant for emerging technology and not for permanent reimbursement. This leads to an uncertain situation for healthcare organizations that consider investing in artificial intelligence screening programs in the long run. Moreover, the integration of AI platforms with EHR systems, primary care workflows, and referral systems takes a lot of time and effort. These implementation challenges continue to slow adoption, particularly among smaller healthcare providers002E

What Opportunities Exist in the U.S. AI-Driven Diabetic Retinopathy Screening Market?

Payer-Directed Population Health Screening Programs

Medicare Advantage plans and Medicaid managed care organizations represent a major growth opportunity for the market. Many payers are expanding AI-based retinal screening to improve diabetes quality measures and reduce healthcare costs associated with preventable vision loss. Payer-sponsored screening initiatives are creating new deployment opportunities beyond traditional health system procurement.

Source: Polaris Market Research Analysis

Segment and Regional Leaders at a Glance

According to Polaris Market Research, Autonomous AI leads the market while Assistive AI the fastest-growing region.

• Dominant Technology Segment: Autonomous AI
• Fastest-Growing Technology Segment: Assistive AI
• Largest Care Setting Segment: Primary Care
• Fastest-Growing Care Setting Segment: Retail Clinics
• Largest End User Segment: Health Systems
• Fastest-Growing End User Segment: Payers

U.S. AI-Driven Diabetic Retinopathy Screening Market Segmentation Analysis

The report provides a comprehensive analysis of the U.S. AI-driven diabetic retinopathy screening market by technology, care setting, and end user to identify key revenue-generating and high-growth segments.

U.S. AI-Driven Diabetic Retinopathy Screening Market by Technology

What is the Largest Technology Segment in the AI-Driven Diabetic Retinopathy Screening Market?

Autonomous AI dominated the U.S. AI-powered diabetic retinopathy screening market share in 2025, with a 53.70% revenue share. This is due to the commercialization of LumineticsCore, which is the first FDA De Novo-authorized autonomous AI diagnostic solution for diabetic retinopathy. It allows primary care doctors and endocrinologists to screen retinas during routine visits without needing an immediate analysis from specialists. This has significantly expanded access to diabetic eye screening.

Which Technology Segment is Growing Fastest in the AI-Driven Diabetic Retinopathy Screening Market?

The assistive AI segment is expected to register the fastest CAGR of approximately 11.70% during the forecast period. Growth is supported by increasing use of AI-assisted image analysis, referral prioritization tools, and multi-disease retinal screening platforms in ophthalmology practices and health systems.

U.S. AI-Driven Diabetic Retinopathy Screening Market by Care Setting

Which Care Setting Leads the U.S. AI-Driven Diabetic Retinopathy Screening Market?

Primary care represented the largest market share of 49.70% in 2025. Combining AI screening in routine diabetes screening increases screening rates while reducing the need for specialist referral. Health systems and Federally Qualified Health Centers (FQHCs) have reported higher patient screening completion after implementing AI-based screening in primary care settings.

Which Care Setting is Growing Fastest in the U.S. AI-Driven Diabetic Retinopathy Screening Market?

The retail clinic segment is projected to grow at the fastest CAGR of approximately 11.90% during the forecast period. Expansion of chronic disease services by pharmacy-based clinics and improved access for uninsured and underserved patients are supporting market growth. AI retinal screening is also emerging as a valuable preventive service within retail healthcare networks.

U.S. AI-Driven Diabetic Retinopathy Screening Market by End User

Which End User Leads the U.S. AI-Driven Diabetic Retinopathy Screening Market?

Health systems captured the largest market share of 46.70% in 2025. Large health systems have the ability to deploy AI screening technologies in numerous primary care and specialty care facilities. Many academic medical centers also use AI retinal screening as part of broader diabetes population health programs.

Which End User Segment is Growing Fastest in the U.S. AI-Driven Diabetic Retinopathy Screening Market?

The payer segment is expected to record the fastest CAGR of approximately 12.10% during the forecast period. Medicare Advantage, Medicaid MCOs, and private payers continue to invest in AI retina screenings to increase preventive care, address screening gaps, and lower future costs of vision-related care. These programs are creating new funding opportunities for AI screening beyond traditional health system procurement.

 

Source: Polaris Market Research Analysis

Segment Summary Table

Segment	Category	2025 Status	Forecast CAGR	Key Driver
Autonomous AI	Technology	Largest share, 53.70%	High	FDA De Novo authorization and primary care integration
Assistive AI	Technology	Fastest growing, ~11.70% CAGR	High	Multi-disease retinal AI and ophthalmology network adoption
Primary Care	Care Setting	Largest share	High	Point-of-care diabetes visit integration and FQHC deployment
Retail Clinics	Care Setting	Fastest growing,	High	Pharmacy health clinic chronic disease service expansion
Health Systems	End User	Largest share	High	Enterprise AI screening program deployment at scale
Payers	End User	Fastest growing	High	HEDIS quality measure improvement and care gap closure programs

Source: Polaris Market Research Analysis

Competitive Landscape and Key Players

The U.S. AI-driven diabetic retinopathy screening market is moderately concentrated. Competition includes autonomous AI developers, assistive AI providers, retinal imaging companies, and large technology firms. Key differentiators include FDA authorization, clinical validation, EHR integration, reimbursement support, hardware compatibility, and successful deployment across health systems and Federally Qualified Health Centers (FQHCs).

Competitive Positioning Table

Company	Est. Market Position	Primary Focus	Geographic Focus	In Report
Digital Diagnostics	Top 3	Autonomous AI (LumineticsCore) first FDA De Novo authorized platform for diabetic retinopathy	US nationwide, FQHC and health systems	Yes
Eyenuk	Top 3	Autonomous AI (EyeArt) FDA De Novo authorized; retail and primary care deployment	US, global	Yes
AEYE Health	Top 5	Autonomous AI screening with payer-directed program partnerships	US, Israel	Yes
Google Health / Verily	Top 5	Deep learning retinal AI development and health system partnerships	US, global	Yes
Topcon Healthcare	Top 5	Fundus imaging hardware with integrated AI-assisted analysis capabilities	Global, strong US presence	Yes
RetinaLyze	Top 10	Cloud-based AI retinal analysis for clinical and community settings	US, Europe	Yes
Optomed	Top 10	Handheld non-mydriatic fundus cameras with AI screening integration	Global, US expanding	Yes

Source: Polaris Market Research Analysis

Technology and Innovation Landscape 2025–2026

The U.S. AI-driven diabetic retinopathy screening market is advancing through innovation in multi-disease retinal AI analysis, handheld and portable fundus camera integration, EHR-native AI platform deployment, foundation model approaches to retinal image analysis, and payer-integrated data analytics for population health screening program management.

Technology	Adoption Stage	Key Development	Market Impact
Autonomous AI Retinal Diagnostic Platforms	Mainstream adoption	FDA De Novo authorized platforms deployed across FQHCs and primary care health systems	Enables point-of-care DR screening without ophthalmologist review at time of image analysis
Assistive AI Retinal Triage and Reading Center Tools	Growing deployment	AI-prioritized reading queues and automated severity grading for teleophthalmology programs	Improves reading center throughput and reduces time-to-result for specialist-interpreted screening programs
Multi-Disease Retinal AI Analysis	Growing deployment	Simultaneous AI detection of DR, DME, glaucoma, AMD, and cardiovascular risk markers	Increases per-scan clinical value and expands reimbursable service scope per patient encounter
Handheld and Portable Non-Mydriatic Fundus Cameras	Growing deployment	Miniaturized imaging devices enabling retinal screening in mobile health, home care, and rural settings	Expands screening into care settings without fixed imaging infrastructure
EHR-Native AI Platform Integration	Early commercial deployment	Direct integration of AI screening results and referral workflows within Epic, Cerner, and athenahealth systems	Reduces implementation friction and automates patient recall, documentation, and referral generation
Foundation Models for Retinal Image Analysis	Early commercial deployment	Large-scale pre-trained retinal AI models enabling transfer learning across disease detection tasks	Accelerates algorithm development and improves generalizability across diverse patient populations

Source: Polaris Market Research Analysis

Near-term market development will be driven primarily by autonomous AI platform expansion into retail clinic and payer-directed program settings, and the advancement of Category I CMS reimbursement coding for autonomous AI diabetic retinopathy screening.

Who Buys U.S. AI-Driven Diabetic Retinopathy Screening Market Research and Why?

The U.S. diabetic retinopathy screening market report is useful in assessing the commercial potential, the competitive environment, and the reimbursement landscape for developing an investment strategy on program and vendor selection and market entry within the ophthalmology diagnostic and population health management markets in the US.

Buyer / Investor Type	Primary Use Case	Key Insight Sought	Decision Horizon
Health System Strategy Teams	AI retinal screening program evaluation and vendor selection	Platform ROI, EHR integration, and reimbursement pathway	1–3 years
Payer Population Health Teams	Care gap closure program design and vendor contracting	HEDIS measure impact and per-member-per-month cost model	1–3 years
AI Diagnostics Companies	Commercial strategy and market sizing	Segment opportunity, competitive benchmarking, and state priorities	2–5 years
Venture Capital and Private Equity	Investment evaluation in AI ophthalmology companies	Market growth durability and reimbursement risk assessment	3–7 years
FQHC and Community Health Networks	Technology procurement and grant program planning	Platform cost, FDA authorization status, and deployment requirements	1–3 years

Source: Polaris Market Research Analysis

What are the Barriers to Entering the Market?

• FDA clearance: It is necessary for De Novo or 510(k) clearance to be granted after considerable clinical evidence and regulation process.
• CMS reimbursement: The Permanent Category I CPT Reimbursement is developed at the moment.
• Clinical proof: Healthcare providers need clinical evidence of the system's efficiency and validity.
• Integration with EHR systems: Integration with such systems as Epic and Cerner needs time and technical development.
• Long sales cycle: Sales cycle for healthcare enterprise procurement typically takes up to 12-24 months due to several stages of approval.
• Dependence on hardware: AI platforms are hardware dependent and require using non-mydriatic fundus cameras.

Premium Insights and Forward Outlook

Category I CMS Reimbursement as the Defining Commercial Inflection Point

Permanent Category I CMS reimbursement is expected to be a major milestone for the U.S. market. This would remove any ambiguity surrounding reimbursement and promote wider usage by hospitals, primary care clinics, Medicare, Medicaid, and private health insurers. Industry players are still developing the necessary clinical data for achieving Category I CPT coding and this is expected between 2026 and 2029.

Multi-Disease Retinal AI as the Next Revenue Expansion Layer

The availability of AI solutions that detect different types of retinal diseases with one scan will create additional opportunities in the market. Apart from diabetic retinopathy, they can be used to detect diabetic macular edema, glaucoma, age-related macular degeneration, and hypertensive retinopathy. The identification of several conditions makes such screening more clinically valuable and financially rewarding.

Cost Benchmarking Table

Product / Service Type	Est. Price Range (USD)	Key Cost Driver	Complexity Tier
Autonomous AI Retinal Screening Platform License (per site per year)	USD 15,000–USD 60,000	Site volume, EHR integration scope, and support tier	Standard-High
Non-Mydriatic Fundus Camera (handheld)	USD 5,000–USD 15,000	Image sensor quality and connectivity features	Standard
Non-Mydriatic Fundus Camera (tabletop, clinical grade)	USD 10,000–USD 35,000	Resolution, auto-capture capability, and software integration	Standard-High
Enterprise Health System AI Screening Program (multi-site)	USD 200,000–USD 1,500,000+ annually	Site count, integration complexity, and service level	Enterprise
Payer-Directed Screening Program (per-member per month)	USD 2–USD 8 per diabetic member per month	Member population size and screening frequency	Standard
AI Reading Center Assistive Tool License	USD 20,000–USD 80,000 per year	Volume of reads and specialist reviewer seats	High

Source: Polaris Market Research Analysis

Key Players

• AEYE Health Ltd.
• Altris AI Inc.
• Annexa Inc.
• Digital Diagnostics Inc.
• Eyenuk Inc.
• Google Health (Verily Life Sciences LLC)
• IDx Technologies Inc.
• Optomed Plc
• Retinal AI Ltd.
• RetinaLyze A/S
• Topcon Healthcare Inc.
• Voxeleron LLC

Industry Developments

• May 2026: Duke Eye Center introduced the first wide-scale AI-based diabetic retinopathy screening program in the U.S., using FDA-approved autonomous AI screening system in endocrinology clinics for prompt diagnosis at the point of care(source: dukeeyecenter.duke.edu)
• October 2024: Eyenuk collaborated with the American Academy of Ophthalmology (AAO) in order to promote AI-based diabetic retinopathy screening in disadvantaged areas of Delaware through EyeCare America program(source: www.ophthalmologytimes.com).

Market Segmentation

By Technology Outlook (Revenue, USD Million, 2021–2034)

• Autonomous AI
• Assistive AI
• Cloud Image Analysis

By Care Setting Outlook (Revenue, USD Million, 2021–2034)

• Primary Care
• Retail Clinics
• Ophthalmology Networks
• Federally Qualified Health Centers (FQHCs)
• Other Care Settings

By End User Outlook (Revenue, USD Million, 2021–2034)

• Health Systems
• Payers
• Employers and Employer Health Plans
• Public Programs (Medicaid, FQHC, IHS)
• Others

Report Scope

Report Attributes	Details
Market Size in 2025	USD 184.15 Million
Market Size in 2026	USD 223.76 Million
Revenue Forecast by 2034	USD 1,081.73 Million
CAGR	21.74% from 2026 to 2034
Base Year	2025
Historical Data	2021–2024
Forecast Period	2026–2034
Quantitative Units	Revenue in USD Million and CAGR from 2026 to 2034
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends
Segments Covered	By Technology | By Care Setting | By End User
Geographic Scope	US – with state-level focus on California, Texas, Florida, New York, Illinois, Pennsylvania, Ohio, Georgia, North Carolina, Arizona
Competitive Landscape	Industry Trend Analysis (2025); Company Profiles including overview, financial information, product benchmarking, and recent developments
Report Format	PDF + Excel
Customization	Report customization available as per requirements with respect to states, segments, and end-user types.